{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '3.', 'Histologically or cytologically confirmed ED SCLC (extensive stage disease at', 'initial diagnosis), with ongoing clinical benefit (SD, PR, or CR per RECIST v.1.1)', 'following completion of 4 cycles of first-line platinum-based therapy (cisplatin or', 'carboplatin in combination with etoposide or irinotecan).', '5.', 'Subject is eligible to be randomized at least 3 but no more than 9 weeks from Day', '1', 'of the fourth cycle of first-line platinum-based chemotherapy.', 'Section 5.2.1 Inclusion Criteria', 'Criterion 9f previously read:', 'Calculated creatinine clearance > 30 mL/min by the Cockroft-Gault formula (Refer to', 'Appendix E)', 'Has been changed to read:', 'Calculated creatinine clearance > 30 mL/min by the modified Cockroft-Gault formula', '(Refer to Appendix E)', 'Section 5.2.2 Exclusion Criteria', 'Criterion 1, 2, 4, and 12 previously read:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for the', 'disease under study.', '2.', 'Any disease-directed radiotherapy (except PCI or pre-planned radiotherapy for CNS', 'metastases present prior to start of first-line therapy and non-progressing) after last', 'dose of first-line chemotherapy.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '166']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '(NYHA) Class III - IV heart failure (refer to Appendix E) within 6 months prior to', 'randomization.', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD)- - or indolinobenzodiazepine-', 'based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known', 'hypersensitivity or other contraindications to rovalpituzumab tesirine or excipient', 'contained in the drug formulation.', 'Has been changed to read:', '1.', 'Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint', 'inhibitors, other monoclonal antibodies, antibody-drug conjugates,', 'radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any', 'other anti-cancer therapy than that described in Inclusion Criteria 3 - 5 for SCLC.', '2.', 'Any disease-directed radiotherapy (except PCI, palliative radiotherapy to a', 'radiographically documented non-progressing lesion for symptom control, or pre-', 'planned radiotherapy for CNS metastases present prior to start of first-line therapy', 'and non-progressing) after last dose of first-line chemotherapy.', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial', 'infarction, or cardiac symptoms consistent with New York Heart Association', '(NYHA) Class III - IV heart failure (refer to Appendix F) within 6 months prior to', 'randomization.', '12.', 'Any prior exposure to a pyrrolobenzodiazepine (PBD-based) or', 'indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine', 'clinical trial, or known hypersensitivity or other contraindications to rovalpituzumab', 'tesirine or excipient contained in the drug formulation.', '167']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Section 5.2.3.1 Prior Therapy', 'First paragraph previously read:', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', 'irinotecan; administration of the last cycle of first-line chemotherapy must be at least', '3 weeks but no more than 9 weeks prior to randomization.', 'Has been changed to read:', 'Subjects will have received first-line platinum-based chemotherapy consisting of 4 cycles', 'of treatment with combination of either cisplatin or carboplatin with etoposide or', 'irinotecan; administration of Day 1 of the last cycle of first-line chemotherapy must be at', 'least 3 weeks but no more than 9 weeks prior to randomization. Subjects previously', 'treated for LD-SCLC are not eligible.', 'Section 5.2.3.2 Concomitant Therapy', 'Last paragraph, last sentence previously read:', 'However, due to the potential for rovalpituzumab tesirine-related skin photosensitivity,', 'subjects should be advised during treatment and for 30 days after last treatment to avoid', 'unprotected sun exposure, use a broad spectrum sunscreen with a sun protection factor', '(SPF) of at least 30 and re-apply sunscreen as activity-appropriate, and wear protective', 'clothing, a broad-brimmed hat, and sunglasses when outdoors or when driving or riding in', 'a car for more than 1 hour.', 'Has been changed to read:', 'However, due to the potential for rovalpituzumab tesirine-related skin photosensitivity,', 'Patients should be advised to avoid direct and indirect sun exposure as much as possible', 'from Cycle 1 Day 1 until 30 days after the final dose. When sun exposure is unavoidable,', 'patients should wear protective clothing and sunglasses, and use a broad-spectrum', 'sunscreen and lip balm (SPF 30 or greater). Thirty-one to ninety days after last dose of', '168']\n\n###\n\n", "completion": "END"}